CORRECTING and REPLACING IPS Strengthens Biologics Expertise with New Team Members, Brian Horowski and Bob Forbes

BLUE BELL, Pa.–(BUSINESS WIRE)–First paragraph, second sentence of release dated March 15, 2023 should read: Brian Horowski, PE joins IPS as Director, Process Technologist, and Bob Forbes, RA, as Director, Process Architecture.

The updated release reads:

IPS STRENGTHENS BIOLOGICS EXPERTISE WITH NEW TEAM MEMBERS, BRIAN HOROWSKI AND BOB FORBES

IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, announces the appointment of two industry-leading professionals to support the company’s continued growth in forefront biologics and other 21st-century therapeutics. Brian Horowski, PE joins IPS as Director, Process Technologist, and Bob Forbes, RA, as Director, Process Architecture.

Mr. Horowski and Mr. Forbes have years of experience working together, specifically in developing and designing bulk biologics and viral vector facilities. They are well-versed in the life sciences industry, collectively bringing over 55 years of experience. Their relationships are strong with many IPS clients, and their distinct expertise aligns well with IPS’ current competencies and continued strategies for growth.

“IPS is truly an awesome company and home to some of the world’s best technologists in the life sciences research, development, and manufacturing industry,” said Tom Piombino, IPS Managing Director, Americas. “Being able to attract top professionals like Brian and Bob, is a testament to what IPS has built here; we are honored to welcome them and share our vision of being the most respected biopharmaceutical EPCMV company in the world.”

Mr. Horowski and Mr. Forbes will be integral to the IPS team of biopharmaceutical experts within our Global Strategy & Technology (GS&T) group. Mr. Horowski will play a key role in bolstering our strategic plan. Additionally, he will design and oversee the implementation of manufacturing processes, equipment, and plants throughout the project lifecycle, from pilot to fully operational. His vast experience in designing bulk drug substance manufacturing facilities for monoclonal antibodies, recombinant proteins, and gene therapies offers a variety of expertise to provide operational improvements for our clients. Mr. Forbes will oversee the design process and be a technical expert on specialized designs to achieve positive results. As a multiskilled architect with extensive experience in the pharmaceutical and biotech industry, his experience includes all phases of project development.

About IPS

IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill, and passion, IPS provides consultancy services, architecture, engineering, project controls, construction management, and compliance services that allow clients to develop and manufacture life-impacting products. Its newest acquisition, Linesight specializes in cost, schedule, risk, program, and project management services in various market sectors, including data centers, life sciences, and high-tech industrial. With the addition of Linesight, IPS has over 3,000 professionals in over 45 offices across 17 countries in the Americas, Europe, Asia Pacific, Southeast Asia, Australia, and the Middle East. For further information, please visit www.ipsdb.com.

Contacts

Dept. of Marketing and Communications

+1.484.344.9234